Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 June;52(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 June;52(2):185-92

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

FOREWORD  NON-STANDARD PET NUCLIDES 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 June;52(2):185-92

Copyright © 2008 EDIZIONI MINERVA MEDICA

language: English

Cross-bridged macrocyclic chelators for stable complexation of copper radionuclides for PET imaging

Anderson C. J. 1, Wadas T. J. 1, Wong E. H. 2, Weisman G. R. 2

1 Mallinckrodt Institute of Radiology Washington University School of Medicine St. Louis, MO, USA 2 Department of Chemistry University of New Hampshire, Durham, NH, USA


PDF


Copper-64 (t1/2=12.7 h; β+: 17.4%; Eβ+max=656 keV; β-: 39%; Eβ-max=573 keV) has emerged as an important non-standard positron-emitting radionuclide for positron emission tomography imaging of diseased tissues. A significant challenge of working with copper radionuclides is that they must be delivered to the living system as a stable complex that is attached to a biological targeting molecule for effective imaging and therapy. Significant research has been devoted to the development of ligands that can stably chelate 64Cu, in particular, the cross-bridged (CB) macrocyclic chelators. This review describes the coordination chemistry and biological behavior of 64Cu-labeled CB complexes.Copper-64 (t1/2=12.7 h; β+: 17.4%; Eβ+max=656 keV; β-: 39%; Eβ-max=573 keV) has emerged as an important non-standard positron-emitting radionuclide for positron emission tomography imaging of diseased tissues. A significant challenge of working with copper radionuclides is that they must be delivered to the living system as a stable complex that is attached to a biological targeting molecule for effective imaging and therapy. Significant research has been devoted to the development of ligands that can stably chelate 64Cu, in particular, the cross-bridged (CB) macrocyclic chelators. This review describes the coordination chemistry and biological behavior of 64Cu-labeled CB complexes.

top of page